Nasdaq Stockholm

Abera Bioscience AB

ISIN SE0014704763Filings at the FI

At a glance

Most recent filing on July 22, 2026 — an open-market purchase by Mats Lundgren on Jul 20, 2026.

We hold 46 visible filings, going back to November 12, 2020.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

Insider trades

What is a MAR filing?

5 of 46 shown

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings at this company, out of 46. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are the price history with every buy marked, the price change beside each line, and any moments with several buyers or buying streaks. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

Mats Lundgren Other senior executive
328,000 SEKOpen-market buy
TradedJul 20, 2026FiledJul 22, 2026
Linus Norén Board member
67,628 SEKOpen-market buy
TradedJun 11, 2026FiledJun 13, 2026
MiRé Holding AB Closely associated: Chief financial officer
59,401 SEKOpen-market buy
TradedFeb 23, 2026FiledFeb 24, 2026
MiRé Holding AB Closely associated: Chief financial officer
41,885 SEKOpen-market buy
TradedFeb 23, 2026FiledFeb 24, 2026
Peter Gönczi Chief executive officer
3,123 SEKOpen-market buy
TradedFeb 19, 2026FiledFeb 20, 2026